Clinical Trial Update: A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis who are on an ARB; the trial is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• DMX-200

Snippet

Sponsor: Dimerix Bioscience Pty Ltd | Conditions: FSGS | Phase 3 | Status: RECRUITING